FX.co ★ 23andMe Agrees To Advance Mirador's Precision Medicines For Immunology, Inflammation

23andMe Holding Co. (ME) announced a collaboration with Mirador Therapeutics on Wednesday. This partnership aims to further develop Mirador's groundbreaking precision therapies for patients suffering from chronic immune-mediated inflammatory and fibrotic diseases. As part of this strategic research agreement, Mirador will leverage 23andMe's extensive database to enhance its proprietary Mirador360 development platform. Currently, 23andMe's stock is trading at $3.42 on the Nasdaq, reflecting a slight decrease of 0.29 percent.